Harvard Bioscience Inc (NASDAQ: HBIO) is a life science instrumentation company that designs, manufactures, and sells products, consumables, software, and services enabling research across molecular, cellular, organ, and preclinical testing applications. Revenue comes from transactional sales of hardware and software systems, recurring consumables, options, upgrades, and post-sales services spanning scientific, installation, and data support. The company organizes its business into two product families: Cellular and Molecular Technology (CMT) and Preclinical, selling to academic and government laboratories, biotechnology and pharmaceutical companies, and contract research organizations (CROs). Founded in 1901 as Harvard Apparatus by Dr. William T. Porter, a Professor of Physiology at Harvard Medical School, the company was incorporated in Delaware in September 2000. A substantial portion of revenues is derived from international operations, with employees across the United States, Germany, and additional facilities in England, Sweden, China, and other locations as of the FY2025 10-K filed March 13, 2026.

Revenue model

Transactional sales of hardware, firmware, and software systems augmented by recurring consumables, options, upgrades, and post-sales services including scientific, installation, and data services. Revenue is generated across both the CMT and Preclinical product families.

Products and services

CMT product family: molecular, cellular, organ, and organoid research tools with applications in bioproduction and in vitro testing. Preclinical product family: implantable and externally worn telemetry systems including the SoHo Small Animal Implantable Telemetry System, behavioral products, isolated organ and surgical products, infusion systems, behavior research systems, turn-key respiratory system solutions including plethysmograph chambers and physiological signal analysis software, inhalation and exposure systems, GLP-capable data acquisition and analysis systems, and the VivaMars behavioral monitoring system launched in 2023. DSI (Data Sciences International) product portfolio acquired in 2018 supports preclinical testing.

Customers and end markets

Primary customers include academic and government laboratories, biotechnology and pharmaceutical companies, and CROs. CMT products serve research in molecular, cellular, organ, and organoid technologies as well as bioproduction and therapy development. Preclinical products serve drug development safety and regulatory compliance testing, with higher-volume industrial customers such as CROs, biotechnology and pharmaceutical companies, and government laboratories as key targets for products like VivaMars.

Value-chain role

Developer and manufacturer of life science research instruments, consumables, and software. Sells direct to end-user research institutions and commercial laboratories. Manufacturing operations centered in Minneapolis, MN (primary U.S. hub following planned closure of Holliston, MA facility under Project Viking) and facilities in Germany, Sweden, and the UK serving as centers of excellence for specific product lines.

Geographic exposure

Operations in the United States (192 full-time, 8 part-time employees as of filing), Germany (51 employees as of filing), with additional leased facilities in Cambridge, England; Stockholm, Sweden; Beijing, China; and Shanghai, China. A substantial portion of revenues is derived from international operations with exposure to USD, British pound, euro, and other currencies.

Source: SEC 10-K, filed 2026-03-13

Industry: Laboratory Analytical Instruments Peers: Alpha Teknova Inc Champions Oncology Inc Niagen Bioscience Inc Standard BioTools Inc IsoPlexis Corp Miromatrix Medical Inc. Personalis Inc Rapid Micro Biosystems, Inc Singular Genomics Systems, Inc. Thermo Fisher Scientific Inc